Cipla, Gilead move to dismiss US antitrust claims over Truvada
MLex Summary: Gilead Sciences and Cipla moved to dismiss claims that they entered into an illegal reverse-payment regarding the drug Truvada. They argued that Cipla never applied for approval from the...To view the full article, register now.
Already a subscriber? Click here to view full article